Clinical studies show significant reductions in body weight and HbA1c in patients with type-2 diabetes, suggesting promising applications beyond metabolic disorders.
Key Points
GLP-1 receptor agonists lead to significant improvements in glycaemic control and weight, enhancing overall patient health.
Clinical findings reveal reductions in HbA1c by 15-20% and lowered cardiovascular events when compared to traditional treatments.
Despite their efficacy, barriers like high costs and a lack of predictive biomarkers hinder widespread use of these therapies.
Future developments in GLP-1 receptor agonists may improve delivery mechanisms and expand their applications in treating various metabolic disorders.